LT2938328T - Monolitinė farmacinė forma, skirta modifikuotam aktyviųjų sudedamųjų dalių derinio atpalaidavimui - Google Patents
Monolitinė farmacinė forma, skirta modifikuotam aktyviųjų sudedamųjų dalių derinio atpalaidavimuiInfo
- Publication number
- LT2938328T LT2938328T LTEPPCT/EP2013/077939T LTEP2013077939T LT2938328T LT 2938328 T LT2938328 T LT 2938328T LT EP2013077939 T LTEP2013077939 T LT EP2013077939T LT 2938328 T LT2938328 T LT 2938328T
- Authority
- LT
- Lithuania
- Prior art keywords
- active ingredient
- modified release
- pharmaceutical form
- ingredient combination
- monolithic pharmaceutical
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE201210113098 DE102012113098A1 (de) | 2012-12-27 | 2012-12-27 | Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination |
| DE102013101049 | 2013-02-01 | ||
| PCT/EP2013/077939 WO2014102253A1 (de) | 2012-12-27 | 2013-12-23 | Monolithische arzneiform zur modifizierten freisetzung einer wirkstoffkombination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2938328T true LT2938328T (lt) | 2023-11-27 |
Family
ID=49911528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2013/077939T LT2938328T (lt) | 2012-12-27 | 2013-12-23 | Monolitinė farmacinė forma, skirta modifikuotam aktyviųjų sudedamųjų dalių derinio atpalaidavimui |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20150343067A1 (lt) |
| EP (1) | EP2938328B1 (lt) |
| KR (1) | KR102220130B1 (lt) |
| AU (1) | AU2013369379B2 (lt) |
| BR (1) | BR112015015483A8 (lt) |
| CA (1) | CA2895609C (lt) |
| EA (1) | EA032456B1 (lt) |
| HU (1) | HUE063546T2 (lt) |
| IL (1) | IL239670B (lt) |
| LT (1) | LT2938328T (lt) |
| MX (1) | MX370067B (lt) |
| PH (1) | PH12015501487B1 (lt) |
| PT (1) | PT2938328T (lt) |
| RS (1) | RS64741B1 (lt) |
| SA (1) | SA515360671B1 (lt) |
| SI (1) | SI2938328T1 (lt) |
| UA (1) | UA118099C2 (lt) |
| WO (1) | WO2014102253A1 (lt) |
| ZA (1) | ZA201505084B (lt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2959887T (lt) * | 2014-06-26 | 2019-03-12 | Hennig Arzneimittel Gmbh&Co. Kg | Vaistai galvos svaigimo, atsiradusio dėl įvairių priežasčių, gydymui |
| US20230218583A1 (en) | 2020-04-17 | 2023-07-13 | Honeybrains, Llc | Compositions and methods for treating neuropsychiatric disorders |
| AU2022270208A1 (en) * | 2021-05-05 | 2023-12-07 | Lyndra Therapeutics, Inc. | Gastric residence systems comprising methadone |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005014141B4 (de) * | 2005-03-23 | 2006-12-21 | Hennig Arzneimittel Gmbh & Co. Kg | Tablettenförmige Retardzubereitung gegen Schwindel |
| DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
| DE102011075354A1 (de) * | 2011-05-05 | 2012-11-08 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur gezielten Freigabe von Wirkstoffen |
| LT2704698T (lt) * | 2011-05-05 | 2019-11-25 | Hennig Arzneimittel Gmbh&Co Kg | Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui |
-
2013
- 2013-12-23 KR KR1020157018883A patent/KR102220130B1/ko active IP Right Grant
- 2013-12-23 US US14/655,053 patent/US20150343067A1/en not_active Abandoned
- 2013-12-23 RS RS20230858A patent/RS64741B1/sr unknown
- 2013-12-23 PT PT138155163T patent/PT2938328T/pt unknown
- 2013-12-23 BR BR112015015483A patent/BR112015015483A8/pt not_active Application Discontinuation
- 2013-12-23 MX MX2015008462A patent/MX370067B/es active IP Right Grant
- 2013-12-23 AU AU2013369379A patent/AU2013369379B2/en not_active Ceased
- 2013-12-23 HU HUE13815516A patent/HUE063546T2/hu unknown
- 2013-12-23 CA CA2895609A patent/CA2895609C/en active Active
- 2013-12-23 UA UAA201507550A patent/UA118099C2/uk unknown
- 2013-12-23 EA EA201500694A patent/EA032456B1/ru unknown
- 2013-12-23 LT LTEPPCT/EP2013/077939T patent/LT2938328T/lt unknown
- 2013-12-23 WO PCT/EP2013/077939 patent/WO2014102253A1/de active Application Filing
- 2013-12-23 EP EP13815516.3A patent/EP2938328B1/de active Active
- 2013-12-23 SI SI201332058T patent/SI2938328T1/sl unknown
-
2015
- 2015-06-23 SA SA515360671A patent/SA515360671B1/ar unknown
- 2015-06-26 PH PH12015501487A patent/PH12015501487B1/en unknown
- 2015-06-28 IL IL239670A patent/IL239670B/en active IP Right Grant
- 2015-07-15 ZA ZA2015/05084A patent/ZA201505084B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150100734A (ko) | 2015-09-02 |
| PT2938328T (pt) | 2023-09-26 |
| CA2895609A1 (en) | 2014-07-03 |
| IL239670A0 (en) | 2015-08-31 |
| IL239670B (en) | 2020-08-31 |
| PH12015501487A1 (en) | 2015-09-21 |
| EA201500694A1 (ru) | 2015-10-30 |
| EP2938328B1 (de) | 2023-07-05 |
| SI2938328T1 (sl) | 2023-11-30 |
| UA118099C2 (uk) | 2018-11-26 |
| WO2014102253A1 (de) | 2014-07-03 |
| ZA201505084B (en) | 2016-12-21 |
| MX2015008462A (es) | 2015-09-23 |
| AU2013369379A1 (en) | 2015-07-16 |
| BR112015015483A8 (pt) | 2019-10-22 |
| CA2895609C (en) | 2021-01-12 |
| US20150343067A1 (en) | 2015-12-03 |
| SA515360671B1 (ar) | 2022-11-13 |
| EA032456B1 (ru) | 2019-05-31 |
| AU2013369379B2 (en) | 2018-03-15 |
| KR102220130B1 (ko) | 2021-02-25 |
| BR112015015483A2 (pt) | 2017-07-11 |
| RS64741B1 (sr) | 2023-11-30 |
| MX370067B (es) | 2019-11-29 |
| PH12015501487B1 (en) | 2015-09-21 |
| HUE063546T2 (hu) | 2024-01-28 |
| EP2938328A1 (de) | 2015-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238713A0 (en) | Self-regulating active pharmaceutical ingredient release | |
| HK1206270A1 (en) | Controlled release formulations for the delivery of hif-1 inhibitors hif-1 | |
| HK1223583A1 (zh) | 透皮釋放活性物質的系統 | |
| IL228441B (en) | Controlled-release pharmaceutical dosage forms | |
| IN2015DN03984A (lt) | ||
| HK1205462A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| IL236465A0 (en) | Pharmaceutical composition for delayed release of active substances | |
| HK1207285A1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| EP2836206A4 (en) | PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE OF DIRECT THROMBINS | |
| ZA201504520B (en) | Active ingredient microparticles | |
| IL236466A0 (en) | Pharmaceutical composition for the release of active components | |
| ZA201505084B (en) | Monolithic dosage form for the modified release of an active ingredient combination | |
| IL227651A (en) | Topical pharmacological formulations containing 220b | |
| PL2585445T3 (pl) | Polimorfy aktywnego składnika farmaceutycznego | |
| PT2704698T (pt) | Forma farmacêutica para a libertação controlada de princípios activos | |
| PL2474529T3 (pl) | Formy krystaliczne farmaceutycznej substancji czynnej | |
| TH1401007646A (th) | รูปแบบยาเวชภัณฑ์สำหรับการปลดปล่อยส่วนประกอบออกฤทธิ์ (Medicament form for release of active ingredients) |